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Abstract
Twenty-five years after the discovery and isolation of the human immunodeficiency virus by French
and American scientists, much progress has been made in basic research, clinical treatment, and
public health prevention measures for acquired immunodeficiency syndrome. Here, we summarize,
in brief, advances that have been achieved and provide some perspectives on future challenges.
Background
The first cases of acquired immunodeficiency syndrome
(AIDS) were described in homosexual men in the US in
1981 [1]. Several years later in 1983 and 1984, respec-
tively, French and American scientists confirmed that the
causative agent for AIDS was a retrovirus, the human
immunodeficiency virus (HIV) [2-4]. Today, 25 years after
the isolation of HIV-1, approximately 25 million individ-
uals have died from AIDS, a number exceeding by 60
times the total number of American casualties in World
War II; and over 33 million people globally are infected
and living with HIV-1. In 2007, 2.7 million individuals
became newly infected with HIV-1, and 2 million AIDS
deaths occurred [5]. Regrettably, half of all people who are
infected with HIV acquire the infection before the age of
25 years, and are killed by AIDS before they turn 35. More
than 95% of new HIV-1 infections arise in low and middle
income nations, populations least likely to have access to
antiretroviral therapy. In the face of these daunting statis-
tics and an unabated pandemic, we look back on progress
achieved in HIV-1 research, treatment, and policies, and
look forward to the challenges that confront AIDS scien-
tists, clinicians and decision-makers for the next 25 years.
Achievements from basic research
The basic research of HIV has made great strides over the
past quarter century. Key discoveries, reviewed here in
brief, have clarified the intricate steps used by the virus
from entry into and exit from the cell (Figure 1). HIV-1 is
an enveloped virus with glycoproteins on its surface [6,7],
responsible for viral entry into cells. The cell's primary
receptor for the virus is the CD4 molecule, and its co-
receptors are members of a family of chemokine receptors
[8,9]. Using the different co-receptors, HIV-1 can differen-
tially infect T-lymphocytes and/or macrophages [10,11].
Entry of the virus into the cytoplasm initiates the disas-
sembly of the HIV core. At this juncture, the virus can be
susceptible to intrinsic cellular antiviral mechanisms
which include tripartite motif protein 5a (TRIM5α), a pro-
tein with a tripartite motif containing a RING domain, a
B-box type 1, and a B-box type 2, followed by a coiled-coil
region [12,13], apolipoprotein B mRNA-editing enzyme,
catalytic polypeptide-like 3G (APOBEC3G) [14,15],
mammalian RNAi (RNA interference) [16,17] and meth-
ylation by a cellular methylase enzyme, protein arginine
methyltransferase 6 (PRMT6) of the arginine residues
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[18,19] of several viral proteins. TRIM5α can target the
viral capsid protein [13]. APOBEC3G can edit HIV RNA
through its cytidine deaminase [20] activity, and in turn
HIV encodes an accessory protein called Vif, which coun-
teracts the effect of APOBEC3G [15,21]. Similarly, meth-
ylation of viral proteins by cellular methyltransferases like
PRMT6 renders them less active and decreases viral repli-
cation [22]. Finally, small cellular RNAs appear to contrib-
ute to a mammalian cellular defense against retroviral
infection [23].
The uncoated HIV-1 reverse transcribes its genomic RNA
in the cytoplasm into a DNA copy (a provirus), which is
then transported into the nucleus for integration into host
chromosomes. Several viral and cellular proteins have
been characterized to participate in these processes
[24,25]. Once integrated, the provirus is transcribed by
the cell's RNA polymerase II machinery with contribu-
tions from cellular transcription factors such as Sp1 and
NF-κB [26]. Later, viral transcription enters a second stage
after the synthesis of the HIV-1 trans-activator of tran-
scription (Tat), an RNA-binding protein. Tat recognizes a
viral trans-activation responsive RNA leader [27,28], and
together with the cellular positive transcription elonga-
tion factor b complex, made up of cyclin-dependant
kinase 9 and cyclin T1[29,30], enhances the initiation and
processivity of HIV-1 transcription by several hundred
fold. Transcribed viral RNAs are next subject to post-tran-
scriptional regulation by HIV-1 Rev and cellular factors
Crm1 and RNA helicases [31,32] to export unspliced and
partially spliced RNAs from the nucleus into the cyto-
plasm for translation.
The viral unspliced RNA (around nine kilobases in size) is
also the genomic RNA, which is encapsidated into the
newly assembled viral particle as a dimer [33,34]. Encap-
sidation of the dimeric HIV-1 RNA depends on structured
RNA motifs [35,36]. The RNA dimer is captured by the
viral Gag polyprotein. Thereafter, the assembly and bud-
ding of the virus transit via the cell's late endosomal path-
way through multi-vesicular bodies [37,38] employing
cellular ESCRT (endosomal sorting complex required for
A schematic illustration of the life-cycle of HIV-1 during the infection of a human cell Figure 1
A schematic illustration of the life-cycle of HIV-1 during the infection of a human cell. Entry, reverse transcription, 
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transport, proteins that are in multivesicular bodies inside
cells) trafficking proteins [39].
Diagnostics
There has been important progress in regard to HIV diag-
nostics. From the initial availability of an antibody test,
the field has now progressed to be able to monitor directly
viral load in the blood using sensitive polymerase chain
reaction (PCR) assays. The advent of PCR testing has also
represented an important safeguard for the blood supply,
since it is now possible to screen all donated blood sam-
ples for HIV using this sensitive technique [40].
Epidemiology
Much has been accomplished also in regard to better
understanding the epidemiology of HIV transmission. On
a worldwide basis, heterosexual transmission represents
the most important means of HIV acquisition [5]. In con-
trast, however, gay men remain at extremely high risk in
regard to new infections in developed country settings.
Many observers have questioned whether this may be due
to complacency among individuals whose attitude may be
that the drugs will work to prolong their lives on an effec-
tive basis, regardless of whether or not they eventually do
become infected by HIV-1 [5]. It is to be hoped that better
awareness and education will provide the basis for dimi-
nution of the numbers of new infections, as the realiza-
tion sets in that drug resistance will likely become a reality
over the long term and that the drugs may not continue to
work forever. A second consideration is the epidemiologic
observation that large numbers of HIV-infected individu-
als may become prone to a wide array of cancers (for
example, lymphomas and anal carcinomas). This is an
additional reason for individuals to remain HIV-negative
rather than abandoning precautions that would otherwise
protect them against HIV-1. The occurrence of high num-
bers of cancers in HIV-positive individuals is relevant to
both developing as well as developed countries.
Progress in treatment
Without doubt, the most significant headway in the battle
against HIV/AIDS has been the development of effective
antiretroviral drugs that provide important treatment
options for patients infected by HIV. These drugs now
exist in a variety of categories based on the enzymatic tar-
gets and/or cellular targets that are the targets of the drugs
themselves (Table 1). The first drugs were targeted against
viral reverse transcriptase but, in short order, we have seen
the development of anti-HIV drugs that are targeted
against protease, and most recently, integrase inhibitors.
The development of combination therapies has been key
in assuring prolongation of life, to an extent that HIV dis-
ease in almost all developed countries today can be con-
sidered to be a chronic manageable condition, unlike the
death sentence that existed during the initial years of the
epidemic through to the mid 1990s when triple therapies
first became available [41,42].
Of course, it is also fair to state that treatments have
improved over the years, not only because of the effective-
ness of the drugs themselves but also because newer com-
pounds developed to treat HIV disease are far less toxic
than those initially used during the 1980s and 1990s. In
addition, simplicity of dosing has become commonplace,
such that patients can, in some cases, take only one pill
per day, based on a co-formulation that involves two nucl-
eoside/nucleotide reverse transcriptase inhibitors coupled
with a non-nucleoside reverse transcriptase inhibitor. The
ability to simplify dosing, coupled with current treatment
protocols, make current therapies far less toxic than their
predecessors, and this has also had important implica-
tions in another area, that is, today's treatment regimens
are far less prone to the development of drug resistance
than were the initially available combination therapies
[43].
It will be recalled that the first use of PIs was based on
compounds such as saquinavir and indinavir, which at
Table 1: Antiretroviral drugs approved by the US Food and Drug Administration
Nucleoside reverse transcriptase 
inhibitor
Non-nucleoside reverse 
transcriptase inhibitor
Protease inhibitor Entry inhibitor
Zidovudine Nevirapine Saquinavir Maraviroc
Didanosine Delavirdine Ritonavir
Zalcitabine Efavirenz Indinavir Integrase inhibitor
Stavudine Etravirine Nelfinavir Raltegravir
Lamivudine Atazanavir
Abacavir Fosamprenavir Combinations
Tenofovir Tipranavir Six available, combining two or three 
drugs
Emtricitabine Darunavir
Fusion inhibitor
Enfuvirtide (T-20)
Entry and fusion inhibitors prevent HIV-1 infection of cells; integrase inhibitor prevents integration of provirus into cellular chromosome.BMC Medicine 2008, 6:31 http://www.biomedcentral.com/1741-7015/6/31
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that time were used in their native form. The subsequent
development of yet another HIV protease, ritonavir, has
been important for the field, since it has been shown that
ritonavir can significantly boost plasma levels of other PIs
[44]. This has had the consequence of imparting to the
newer generation of PIs a much higher genetic barrier for
resistance, such that an accumulation of multiple muta-
tions is almost always now required in order for a drug to
cease being active against its intended target. This progress
has only been possible as a result of continuous research
over the past decades that have improved our understand-
ing of drug mechanism of action, and pharmacokinetics
and other factors responsible for the development of drug
resistance. It is important as well, to recognize the contri-
butions of social science research in this context and the
fact that proper adherence to antiretroviral drug regimens
has turned out to be a key factor in both the long-term
efficacy of the drugs employed in therapy as well as in
minimizing the likelihood that drug resistance will
develop [45].
Drug resistance
Drug resistance is probably the single most critical factor
responsible for failure of antiretroviral therapy and has
ensured that drug companies and scientists are strongly
motivated to continue to move forward with new anti-
HIV drug discovery programs [46]. In recent years, the
search for anti-HIV drugs has been extended to com-
pounds that might act against cellular rather than viral tar-
gets. Indeed, one such drug now approved for therapy
works by blocking the CCR5 co-receptor that is required
for HIV to gain entry into susceptible CD4 lymphocytes
[8]. The advantage of a drug that targets cellular proteins
rather than viral enzymes is that this should theoretically
minimize the likelihood that viral mutagenesis might give
rise to drug resistance. Indeed, we now know that other
cellular factors might also become important targets for
anti-HIV chemotherapy [47]. Good examples of strong
leads include the APOBEC3G series of proteins that are
impacted by viral proteins such as Vif, and cellular LEDGF
proteins that are essential for the proper function of the
viral integrase enzyme [15,47].
Perspectives and challenges
Looking forward, multiple challenges confront HIV-1
researchers, clinicians and policy makers. Below, we high-
light a few of these issues.
Sustainability of antiretroviral treatment
The United Nations estimate that only 7% of people in
developing countries have access to antiretroviral drugs,
and that only 20% of people worldwide are reached by
HIV-1 prevention programs [5]. At recent international
conferences on AIDS, the point has repeatedly been made
that more people become newly infected by HIV each year
than the number that are newly able to gain access to
antiretroviral drugs. The drug access that is now being pro-
vided by the Global Fund to Fight AIDS, TB, and Malaria
and the US-sponsored President's Emergency Plan for
AIDS Relief are having major impact in this regard [48].
Nevertheless, it must be recognized that HIV-1 drug treat-
ment is chronic, unabated life-long therapy. Thoughtful
policies that save today's lives and countenance the sus-
tained resources needed to continue future long-term
treatment have to be developed.
Prevention strategies, microbicides, and vaccines
Although HIV treatment has improved steadily since the
introduction of the first antiretroviral drugs, for example,
AZT and ddI, during the late 1980s, most of this progress
has been limited to developed countries. In contrast,
access to anti-HIV drugs continues to be problematic in
most of the developing world. Sadly, for millions of HIV-
infected individuals, access to anti-HIV therapy is not yet
a reality [5]. Anti-HIV drugs may contribute much to the
prevention of infection. As an example, it is well-known
that the most important correlate of HIV transmission is
the level of plasma viremia within an infected individual.
Since anti-HIV drugs act to limit viral replication, they
also lower plasma viremia, and it is hoped to levels that
are non-detectable by very sensitive PCR assays [49]. As a
consequence, patients whose plasma viremia is well sup-
pressed can potentially be regarded as non-infectious for
sexual contacts. This statement, although somewhat con-
troversial in terms of public health recommendations,
establishes rationale to treat patients on as widespread a
basis as possible, in order to lower viral loads and hope-
fully diminish overall levels of HIV transmission. This is
important, since practical progress in regard to prevention
strategies involving HIV-1 has been almost negligible
[50].
In regard to preventive HIV vaccines, two phase 3 clinical
trials, one involving the viral protein gp160, and a second,
involving a recombinant adenovirus vector containing
viral proteins, have failed [51]. Indeed, the latter trial may
have resulted in a greater number of individuals in the
experimental rather than in the placebo arm becoming
infected. There is widespread consensus that it will be at
least another decade before phase 3 trials are ready to
begin once again with vaccines that are designed to pre-
vent new HIV transmissions.
Similarly, there has been frustration in regard to the use of
anti-HIV vaginal microbicides to prevent infection. A large
number of phase 3 clinical trials, involving non-specific
polyanionic substances, have failed [50]. These have
included trials of nonoyxynol-9, sulfated polysaccharides,
and other substances; in which again, it appears that the
women who received the anti-HIV microbicides may actu-BMC Medicine 2008, 6:31 http://www.biomedcentral.com/1741-7015/6/31
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ally have suffered greater numbers of infections than
women in the control arm of the studies, perhaps because
the substances used were toxic to vaginal mucosal tissue,
thus promoting infection in the experimental arm.
It is now unlikely that further studies using non-specific
approaches of the sort mentioned above will be under-
taken. Rather, there is strong consensus that future micro-
bicide trials should be conducted with antiretroviral drugs
that could perhaps be formulated as vaginal gels and that
might protect against HIV transmission from an infected
male partner. A type of compound that probably has the
strongest rationale in this context is a CCR5 antagonist;
several such compounds have now been shown in animal
models to be protective against transmission of simian
immunodeficiency virus. Whether or not CCR5 antago-
nists formulated as gels will also protect against HIV trans-
mission is not yet known. In addition, there is also
rationale to develop certain nucleoside(tide) and/or non-
nucleoside reverse transcriptase inhibitors as anti-HIV
vaginal microbicides. Research in this area is continuing
apace to evaluate these various prevention strategies [52].
An approach similar to the above, also now undergoing
phase 3 clinical testing, is that of pre-exposure prophylaxis
(PREP) [53]. People who are susceptible to HIV infection
are asked to take antiretroviral drugs on a prophylactic
rather than therapeutic basis. Clinical studies now under-
way are evaluating the co-formulation of tenofovir
together with FTC (Truvada). The reason for choosing
these two drugs in combination is that both of them have
relatively long half-lives, meaning that dosing is only
required once per day. The hope is that these drugs will be
able to interfere with early reverse transcription events
that may transpire immediately after infection, thereby
preventing the virus from being able to take root within
the body. Results of these studies should be available
within 1 to 2 years.
One issue that must be considered, however, is drug resist-
ance. Of course, it may be difficult to assess whether or not
antiretroviral drugs when used as preventives will work, if
the viruses being transmitted by infected partners are
themselves drug resistant. Also, there is a danger that an
individual may choose to avail themselves of this PREP
approach while being in the window period for serocon-
version, at a time that high viral loads are present, thus
representing a scenario whereby selection of drug resist-
ance might occur. This notwithstanding, many observers
now consider the PREP approach to be the most promis-
ing of all strategies for prevention of HIV transmission
[52].
Pediatric infections
Almost all HIV-infected pregnant women in developed
countries now receive triple therapy during the course of
pregnancy to prevent mother-to-child transmission of the
virus. This has resulted in the virtual elimination of the
pandemic of native-born pediatric AIDS in all developed
country settings. Sadly, such progress has not been real-
ized in developing countries [5].
Circumcision
Another success story in relation to prevention has been
the understanding that male circumcision may help to
reduce female-to-male transmission of HIV by as much as
60% [54]. This is presumably because circumcision elim-
inates the foreskin that contains penile tissue rich in Lang-
erhans cells that are thought to be important portals of
entry for HIV into the body. Hence, elimination of this tis-
sue may diminish the likelihood of transmission.
Conclusion
The theme of World AIDS Day in 2007 was 'leadership'.
As AIDS moves from the 20th into the 21st century, the
world today with its increased globalization is much dif-
ferent than it was in 1983; and over the next 25 years, it
will change again. For example, several well-regarded eco-
nomic sources have projected that China will have over-
taken the US by 2040 to become the world's largest
economy, with India capturing third place. Although
China's official AIDS statistics in 2005 reveal a relatively
few, 650,000, HIV-cases, against a total population of 1.3
billion people, China's future HIV numbers will undoubt-
edly increase significantly [55]. It seems inescapable that
a long-term solution for HIV/AIDS must include a com-
mitment of leadership and resources from China, on a
scale no weaker than the recent support of the Olympic
Games.
Our achievements over the past 25 years, as outlined
above, have come, in part, because of outstanding, capa-
ble leaders in all facets of HIV-1 research. A concern dis-
cussed at the International AIDS Society's XVII
International AIDS Conference in Mexico City was how to
develop, nurture, and avoid a shortfall in new AIDS lead-
ers. Realistically, major initiatives such as the develop-
ment of successful prophylactic HIV-vaccines and effective
topical antiviral microbicides require perseverance that
spans a decade or more with little reason to expect short-
term success. Thus, looking ahead, we must attain sustain-
ability of economic resources in order to assure delivery of
antiretroviral treatment in developing countries, while
not neglecting the need to develop the new human lead-
ership that will be essential to sustain and accelerate the
global campaign against HIV/AIDS.BMC Medicine 2008, 6:31 http://www.biomedcentral.com/1741-7015/6/31
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